Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
Trial record 1 of 1 for:    CYC682 – 12
Previous Study | Return to List | Next Study

A Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia (SEAMLESS)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified September 2012 by Cyclacel Pharmaceuticals, Inc..
Recruitment status was:  Active, not recruiting
Information provided by (Responsible Party):
Cyclacel Pharmaceuticals, Inc. Identifier:
First received: February 21, 2011
Last updated: August 17, 2015
Last verified: September 2012
This Phase 3 study assesses two drug regimens as the initial treatment of patients who are at least 70 years of age and have newly diagnosed acute myeloid leukemia (AML) for whom the doctor does not recommend the use of standard intensive treatment or the patient has decided not to receive standard intensive treatment after being fully informed about its benefits and risks by his/her doctor. The two drug regimens are sapacitabine administered in alternating cycles with decitabine, or decitabine alone. The purpose of the study is to learn which drug regimen is more likely to keep AML in check as long as possible.

Condition Intervention Phase
Acute Myeloid Leukemia
Drug: Sapacitabine and decitabine
Drug: Decitabine
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients With Newly Diagnosed Acute Myeloid Leukemia

Resource links provided by NLM:

Further study details as provided by Cyclacel Pharmaceuticals, Inc.:

Primary Outcome Measures:
  • Overall survival [ Time Frame: up to 43 months ]

Secondary Outcome Measures:
  • Complete remission with duration [ Time Frame: Up to 43 months ]
  • Complete remission with incomplete platelet count recovery and duration [ Time Frame: up to 43 months ]
  • Partial remission with duration [ Time Frame: up to 43 months ]
  • Hematological improvement with duration [ Time Frame: up to 43 months ]
  • Stable disease with duration [ Time Frame: up to 43 months ]
  • Number of units of blood product transfused [ Time Frame: up to 43 months ]
  • Hospitalized days [ Time Frame: up to 43 months ]
  • 1-year survival [ Time Frame: up to 43 months ]

Estimated Enrollment: 485
Study Start Date: January 2011
Estimated Study Completion Date: November 2015
Estimated Primary Completion Date: October 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Arm A
Sapacitabine and decitabine
Drug: Sapacitabine and decitabine
Sapacitabine administered in alternating cycles with decitabine
Active Comparator: Arm C
Drug: Decitabine
Decitabine alone

Detailed Description:
This is a multicenter, randomized, Phase 3 study comparing two drug regimens (arms) as the front-line treatment of elderly patients aged 70 years or older with newly diagnosed acute myeloid leukemia (AML) who are not candidates for intensive induction chemotherapy. In Arm A, sapacitabine is administered in alternating cycles with decitabine, and in Arm C decitabine is administered alone. The primary efficacy endpoint is overall survival. The study is designed to demonstrate an improvement in overall survival of Arm A versus Arm C.

Ages Eligible for Study:   70 Years and older   (Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Newly diagnosed AML based on WHO classification
  • Age 70 years or older for whom the treatment of choice is low-intensity therapy by investigator assessment or who has refused intensive induction therapy recommended by investigator
  • ECOG performance status 0-2
  • Adequate renal function
  • Adequate liver function
  • Able to swallow capsules
  • Agree to practice effective contraception
  • Ability to understand and willingness to sign the informed consent form

Exclusion Criteria:

  • AML is of the sub-type of acute promyelocytic leukemia or extramedullary myeloid tumor without bone marrow involvement
  • Having received any systemic anti-cancer therapy for AML or received treatment with hypomethylating agents or cytotoxic chemotherapy for the preceding MDS or MPD
  • Known or suspected central nervous system (CNS) involvement by leukemia
  • Uncontrolled intercurrent illness
  • Known hypersensitivity to decitabine
  • Known to be HIV-positive
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01303796

  Show 118 Study Locations
Sponsors and Collaborators
Cyclacel Pharmaceuticals, Inc.
Study Chair: Hagop Kantarjian, M.D. M.D. Anderson Cancer Center
  More Information

Responsible Party: Cyclacel Pharmaceuticals, Inc. Identifier: NCT01303796     History of Changes
Other Study ID Numbers: CYC682-12
Study First Received: February 21, 2011
Last Updated: August 17, 2015

Keywords provided by Cyclacel Pharmaceuticals, Inc.:

Additional relevant MeSH terms:
Leukemia, Myeloid
Leukemia, Myeloid, Acute
Neoplasms by Histologic Type
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents
Enzyme Inhibitors processed this record on May 25, 2017